# Tiotropium Respimat Pharmacokinetic Study in COPD

> **NCT01222533** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 154 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Tiotropium medium
- **DRUG:** Tiotropium low
- **DRUG:** Tiotropium high
- **DRUG:** Tiotropium 18mcg
- **DRUG:** Tiotropium placebo

## Key facts

- **NCT ID:** NCT01222533
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2011-11
- **Final completion:** —
- **Target enrollment:** 154 (ACTUAL)
- **Last updated:** 2014-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01222533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01222533, "Tiotropium Respimat Pharmacokinetic Study in COPD". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01222533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*